| 摘要 |
A vaccine for Marek's disease using mutant strains of a serotype 2 field isolate, designated 471B/1, is disclosed. The mutant viruses, which are produced by serial passage of 471B/1 in cell culture, not only retain effective immunizing ability against Marek's disease virus, but which also exhibit reduced enhancement of lymphoid leukosis in comparison to non-passaged 471B/1 and conventional serotype 2 vaccines. These viruses or immunogenic components thereof can be formulated into monovalent and polyvalent vaccines.
|
